Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. - Wikidata - wikimedia - TriplyDB

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.

http://www.wikidata.org/entity/Q33680252

about

Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis Chemotherapy-induced peripheral neurotoxicity: a critical analysis Treatment of multiple myeloma bone disease: experimental and clinical data.Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study.A Case of Drug-Induced Hepatitis due to Lenalidomide.Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India Lenalidomide enhances anti-myeloma cellular immunity Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Thyroid dysfunction from antineoplastic agents.A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide Evaluation of immunomodulatory drugs in multiple myeloma: single center experience.Challenges in multiple myeloma diagnosis and treatment.A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma).Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma.Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.Cost-effectiveness of lenalidomide in multiple myeloma.Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review.Managing multiple myeloma in the elderly: are we making progress?Efficacy of bortezomib as first-line treatment for patients with multiple myeloma.Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database.Controversies in multiple myeloma: to transplant or not?Novel agents and new therapeutic approaches for treatment of multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.Novel Induction Regimens in Multiple Myeloma.Response to dexamethasone is glucose-sensitive in multiple myeloma cell lines Safety and efficacy of primary thromboprophylaxis in cancer patients.Increased effect of IMiDs by addition of cytokine-induced killer cells in multiple myeloma.Chemotherapy-Related Neurotoxicity.A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.Partial remission of acute myeloid leukemia complicating multiple myeloma following COAP chemotherapy: A case report.Current approaches to the initial treatment of symptomatic multiple myeloma.

P2860

Q21133524-D432D2AD-32B4-4030-99D3-C413C77C144E Q26767418-9A745822-5D0F-4273-998B-D779051E900C Q27010318-9638A8F5-1A15-4DD6-A676-6DE430210EBF Q30868833-FA01E6B4-6D7B-47FE-B289-C5B2FC30B466 Q33393257-5254905D-498A-4656-AEB6-DC4C4F2B73BB Q33395229-9703EE26-5B72-47C1-AB8C-3EC406E446B6 Q33397439-7FA72C4E-FA82-4C1D-9692-D48DBE9FCD88 Q33404348-10F98169-7DBA-40E8-99AE-C67C7C50014D Q33424264-CA163C3C-8B4C-4B6E-9AB5-8A069A516B7B Q33903133-3A4ED502-17FD-453C-A150-4967A0E30C81 Q34040130-2D66DE71-10B0-4086-82F9-2C5CBA506B3A Q34345502-77607CD6-E125-4F95-8B51-49306E78B0CF Q34541542-B3CEBBEC-3E2F-41DE-9718-5ECE108CB471 Q35500038-1D594A8A-AE16-43D0-884A-68F95959945A Q35608564-45D7C1D7-B446-425F-828A-3A3B99B0D426 Q36544516-9EE670BD-27D4-41FA-AB30-0A359E36363E Q36625053-45993BA2-7981-4143-91AB-3BC4EF255516 Q36852225-70E1CA71-87EB-4C93-8BBD-1C8F696D21DD Q36862393-91833161-FCF0-4677-A18C-08CBAACF0FFB Q36963203-75A5979D-A766-407C-9FEA-56D7425F96C3 Q37030249-2711D5B7-AF23-4671-A7DD-E4D18289D549 Q37417591-0469E713-12BE-43E2-BD5C-DB71A64BFACD Q37764870-72C394AD-4E77-468D-A8D6-1370F7D4C0F0 Q37872263-EF4F38E6-AFD1-456E-84DF-AC1E6E259004 Q37888716-75560AB6-6424-49C2-8ADB-AA2A9E2FD23E Q38089497-19445B3D-A5B3-4C1B-B842-02E52E788F28 Q38146900-A7C81991-CE1D-4A18-9962-3062062BD766 Q38242006-D9749896-1FE2-45A3-BE24-4FF122698174 Q38261677-9F18D686-BA47-413A-8C07-7CDA3338ABEC Q38271032-8512118C-EBFE-4183-938F-F6005592033B Q38435358-61177769-D8BC-4E2A-8ECD-2D370A60B399 Q38567017-D2BF6019-9DE3-457F-B96F-9894B673D771 Q38583915-CE59BC85-9530-4AF4-A97F-3EF7CE694C12 Q38826115-DBF835ED-3FC5-4FF3-804F-7A025F5C7DE4 Q38898226-FD6A8996-D390-46FC-91ED-7D2C66A219A9 Q38904676-E0EA8518-CBB7-4917-9076-32FDCB988C2C Q39131099-23B701DF-0BF7-45E2-8E2F-04DDDC485907 Q39681317-56B65E55-75A6-4A1B-859E-12CF23175273 Q40170328-352ED22F-38F5-4EFE-8B99-3FD2C5068C17 Q41819491-2932FD12-B651-4C63-BE44-439D02B4E07D

P2860

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.

http://www.wikidata.org/entity/Q33680252

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Lenalidomide plus dexamethason ...... tive analysis of 411 patients.

@ast

Lenalidomide plus dexamethason ...... tive analysis of 411 patients.

@en

type

label

Lenalidomide plus dexamethason ...... tive analysis of 411 patients.

@ast

Lenalidomide plus dexamethason ...... tive analysis of 411 patients.

@en

prefLabel

Lenalidomide plus dexamethason ...... tive analysis of 411 patients.

@ast

Lenalidomide plus dexamethason ...... tive analysis of 411 patients.

@en

P1433

Q33680252-BA4A9179-4823-4FDB-A8FA-A13839D05B9A

P1476

Q33680252-6C4688B5-9917-4DD0-9762-53186FC5A0C1

P2093

Q33680252-1F57646E-1B80-4549-B8B3-383C1213CBF4

Q33680252-2CEC6239-7A27-4693-BC0B-7A6061665166

Q33680252-3707169F-50AC-4BE9-8804-DAD2D522DEE3

Q33680252-568029A4-7019-4C8F-8463-D6AF21CDC057

Q33680252-7FCB6994-6D6F-4EDA-943E-1E5099983E7A

Q33680252-9B3AC1D1-3C6C-46CF-B0BC-D9697B8B810E

Q33680252-9CD1FD92-6764-47BC-B6C3-181167ED0462

Q33680252-A88BCCB7-2069-4776-8825-82934425818E

Q33680252-C808E98E-91F6-4A92-9021-66EE11343055

Q33680252-D9356272-6291-4C11-AC9D-E80A1C19F8F4

P2860

Q33680252-10A04463-67AF-47C4-A28D-FC66DD3009A9

Q33680252-31D3225C-1206-43EC-AD2C-FC94D1C2C2AA

Q33680252-4BA2DF6C-B33F-4F61-B2D4-DA654C145EC3

Q33680252-69FD1C80-657B-49C3-8CA9-E21150FDA0AC

Q33680252-77E01FA2-3667-4DF2-A652-344A276DB3A7

Q33680252-7CD9CA72-E98B-4990-9FCC-BBA97E3EA001

Q33680252-91FE5AF2-EB58-4A8B-BC77-292DF79EF17C

Q33680252-A332C7E3-F365-4E4A-8C6D-4AE912181081

Q33680252-B4E50001-9D53-418F-B64F-ADCA71771B14

Q33680252-BCAA0274-1673-45C8-8A7F-D3643F93AB60

P304

Q33680252-4328A883-34ED-4672-A227-F94B8706D02C

P31

Q33680252-1C65488C-806E-4741-B497-3907CA572341

P356

Q33680252-0D39AF64-C627-4C50-BEC4-6A599B17403F

P407

Q33680252-4A601F01-B2FF-4DE1-9235-3B89DA302478

P433

Q33680252-17FA82AF-E434-42FB-9943-43674234E63D

P478

Q33680252-41D99076-0EE4-4D59-BAAF-D6E06264118E

P50

Q33680252-3C713C9A-69C2-4B07-9638-5CFF5EBFCBC3

Q33680252-4BB4F8D5-7ADA-44C6-BFC8-F04E631AE3D1

Q33680252-54EBC9C9-C899-4586-A31A-E65CF74AD517

Q33680252-725639C6-AB77-406B-83A8-16267562B243

Q33680252-785AAB4B-15FE-470E-A09E-EF443C471086

Q33680252-8BC95018-26EA-4B06-A81E-DE7EFF3B5362

Q33680252-954D8E35-3BB4-4C7B-955C-01BEA68E2811

Q33680252-B2E6D234-DC85-4585-AC4C-301FD5618611

Q33680252-BBA9CE0D-A523-4E8C-95F1-48F5C0606CFE

P577

Q33680252-78AF1478-06B9-4B69-A4A7-81E8FE87D807

P5875

Q33680252-ADA16EFB-24B3-47CB-8873-38447532D62B

P698

Q33680252-29B6A971-182F-4B0A-8B84-C71899298A0E

P921

Q33680252-0DC36ED0-052C-4234-92A2-40722E35AABC

Q33680252-2A09CDC8-7DDB-450D-A1E1-61B2C6B06446

P932

Q33680252-2A869CBD-10A0-45D2-9F34-800A06393BD8

P356

BLOOD-2009-08-239046

P1433

P1476

Lenalidomide plus dexamethason ...... tive analysis of 411 patients.

@en

P2093

A Keith Stewart

http://www.w3.org/2001/XMLSchema#string

Craig B Reeder

http://www.w3.org/2001/XMLSchema#string

Francesca Gay

http://www.w3.org/2001/XMLSchema#string

Francis Buadi

http://www.w3.org/2001/XMLSchema#string

John A Lust

http://www.w3.org/2001/XMLSchema#string

Joseph R Mikhael

http://www.w3.org/2001/XMLSchema#string

P Leif Bergsagel

http://www.w3.org/2001/XMLSchema#string

Philip R Greipp

http://www.w3.org/2001/XMLSchema#string

Rafael Fonseca

http://www.w3.org/2001/XMLSchema#string

Shaji Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Multiple myeloma.

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.

VAD-based regimens as primary treatment for multiple myeloma.

Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.

P304

1343-1350

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-08-239046

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

Stephen J Russell

S. Vincent Rajkumar

Suzanne R Hayman

Steven R Zeldenrust

P577

2009-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40686038

http://www.w3.org/2001/XMLSchema#string

P698

20008302

http://www.w3.org/2001/XMLSchema#string

P921

P932

2826759

http://www.w3.org/2001/XMLSchema#string